Medicamen Biotech Stock Screener | Share Price & Fundamental Analysis

MEDICAMEQ Pharmaceuticals
Share Price NSE
₹240.92
▼ -0.27 (-0.11%)
2026-04-13 00:00:00
Share Price BSE
₹242.55
▲ 0.10 (0.04%)
2026-04-13 00:00:00
As of April 13, 2026, the Medicamen Biotech share price (NSE: MEDICAMEQ) is ₹240.92 on NSE and ₹242.55 on BSE, down 0.11% from the previous close, with shares trading between ₹232.94 and ₹249.96, and a 52-week range of ₹223.30–₹494.85. Browse MEDICAMEQ balance sheet details to support your investment research. Record your trades in TickJournal's free trading journal and track your portfolio performance.
Medicamen Biotech Market Cap ₹327.12 Cr.
MEDICAMEQ P/E Ratio (TTM) 44.92
Medicamen Biotech P/B Ratio 1.17
EPS (TTM) ₹5.60
Dividend Yield 0.39%
Debt to Equity 0.15
MEDICAMEQ 52 Week High ₹494.85
Medicamen Biotech 52 Week Low ₹223.30
Operating Margin 9.00%
Profit Margin 4.26%
MEDICAMEQ Revenue (TTM) ₹47.00
EBITDA ₹5.00
Net Income ₹2.00
Total Assets ₹297.00
Total Equity ₹213.00

Medicamen Biotech Share Price History - Stock Screener Chart

Screen MEDICAMEQ historical share price movements with interactive charts. Analyze price trends and patterns.

Medicamen Biotech Company Profile - Fundamental Screener

Screen Medicamen Biotech company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for MEDICAMEQ shares.
Sector Healthcare
Industry Pharmaceuticals
Sub-Sector Pharmaceuticals
Segment E
ISIN INE646B01010

Medicamen Biotech Balance Sheet Screener

Screen MEDICAMEQ balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics.
Item 2025 2024 2023 2022 2021 2020 2019
Assets
Total Assets 297 295 279 226 194 181 137
Current Assets 165 160 163 123 96 104 96
Fixed Assets 87 92 93 93 90 34 24
Liabilities
Total Liabilities 0 0 0 0 0 0 0
Current Liabilities 6 3 3 7 8 4 1
Non-Current Liabilities 0 0 0 0 0 0 0
Shareholders' Equity
Total Equity 213 207 193 147 133 121 87
Share Capital 13 13 13 12 12 12 12
Reserves & Surplus 200 194 178 134 121 109 75

Medicamen Biotech Income Statement Screener - Profit & Revenue Analysis

Screen Medicamen Biotech income statement and profit fundamentals. Analyze MEDICAMEQ quarterly results, revenue growth, EBITDA, net profit margins, and EPS using TickJournal's fundamental screener for Medicamen Biotech share price evaluation.
Item 2025-Dec 2025-Sept 2025-Jun 2025-Mar 2024-Dec 2024-Sept 2024-Jun 2024-Mar 2023-Dec 2023-Sept 2023-Jun 2023-Mar 2022-Dec 2022-Sept 2022-Jun
Revenue 47 48 44 35 45 45 44 48 47 44 42 39 36 34 34
Expenses 43 42 38 31 38 39 40 42 42 39 35 32 30 28 27
EBITDA 5 6 5 4 7 6 4 6 6 5 7 7 7 6 7
Operating Profit % 9.00% 11.00% 11.00% -5.00% 15.00% 12.00% 8.00% 12.00% 11.00% 11.00% 17.00% 17.00% 17.00% 17.00% 17.00%
Depreciation 2 2 2 1 2 3 2 2 2 2 2 2 2 2 2
Interest 1 1 1 1 1 1 1 2 1 1 1 1 1 1 1
Profit Before Tax 2 3 2 3 4 2 2 3 3 3 5 4 4 4 4
Tax 1 1 1 1 1 1 1 1 1 1 1 1 0 1 1
Net Profit 2 2 2 2 3 1 1 2 2 2 4 4 4 4 4
EPS 1.21 1.56 1.18 1.47 2.30 0.71 0.63 1.61 1.60 1.17 3.12 3.03 2.98 2.85 2.94

Medicamen Biotech Cash Flow Screener - Liquidity Fundamentals

Screen MEDICAMEQ cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength assessment.
Item 2025-March 2024-March 2023-March 2022-March 2021-March 2020-March 2019-March
Operating Activities -8 -7 -6 4 13 13 4
Investing Activities -1 -6 -6 -9 -18 -37 -15
Financing Activities -2 6 29 4 6 19 -4
Net Cash Flow -11 -6 17 0 1 -5 -14

Medicamen Biotech Shareholding Pattern Screener

See Medicamen Biotech shareholding pattern with promoter, FII, and DII holdings. Check Medicamen Biotech promoter holding and ownership changes for MEDICAMEQ on TickJournal.
Item 2025-Mar 2025-Apr 2025-Jun 2025-Sept 2025-Dec 2024-Mar 2024-Jun 2024-Sept
Promoter Holding 43.16% 40.46% 40.46% 40.46% 40.46% 43.21% 42.99% 42.99%
FII Holding 0.12% 0.22% 0.00% 0.06% 0.02% 0.11% 0.06% 0.06%
DII Holding 0.69% 0.65% 0.64% 0.59% 0.44% 0.99% 1.17% 1.17%
Govt Holding 0.06% 0.05% 0.05% 0.05% 0.05% 0.00% 0.00% 0.00%
Public Holding 33.35% 31.58% 31.50% 33.35% 32.17% 31.95% 31.57% 32.43%
Other Holding 22.63% 27.04% 27.34% 25.50% 26.86% 23.74% 24.21% 23.34%
Shareholder Count 10,435 10,592 10,808 11,177 10,967 10,639 10,652 10,792

Medicamen Biotech Share Dividend Screener - Share Yield Analysis

Check Medicamen Biotech dividend history with payout and yield data. View Medicamen Biotech dividend details including ex-dates and amounts for MEDICAMEQ stock.
Period Dividend Per Share Dividend Yield
2026-March ₹0.00 0.00%
2025-March ₹1.00 0.45%
2024-March ₹1.00 0.21%
2023-March ₹1.00 0.26%
2022-March ₹1.00 0.15%
2021-March ₹1.00 0.16%
2020-March ₹0.00 0.00%
2019-March ₹0.00 0.00%
2018-March ₹0.00 0.00%
2017-March ₹0.00 0.00%

Medicamen Biotech Stock Index Membership

See which indices include Medicamen Biotech stock. Check MEDICAMEQ index membership in NIFTY 50, SENSEX, and other indices on TickJournal.
Medicamen Biotech is not part of any tracked indices.
Only major market indices are tracked in our system.

Medicamen Biotech Market Events Screener - Corporate Actions

Get Medicamen Biotech corporate actions including splits, bonuses, and buybacks. Check Medicamen Biotech stock events that may affect MEDICAMEQ share price.
Announcement Date Record Date Event Type Information Price Impact
Dividend ₹ 1.00 /share -22.18%
Dividend ₹ 1.00 /share 79.23%
Dividend ₹ 1.00 /share -6.07%
Dividend ₹ 1.00 /share -10.33%
Annual General Meeting NA 20.69%
Dividend ₹ 1.00 /share 14.55%
Annual General Meeting NA -9.63%
2026-02-13 2026-02-13 Quarterly Result Announcement NA -6.83%
2025-11-14 2025-11-14 Quarterly Result Announcement NA 7.40%
2025-08-12 2025-08-12 Quarterly Result Announcement NA -4.93%
2025-05-30 2025-05-30 Quarterly Result Announcement NA -0.82%
2025-03-26 2025-03-26 Extraordinary General Meeting NA -16.66%
2025-02-11 2025-02-11 Quarterly Result Announcement NA 6.85%
2024-11-14 2024-11-14 Quarterly Result Announcement NA -14.31%

Medicamen Biotech Competitors Screener - Peer Comparison

Screen MEDICAMEQ competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance for better stock selection.
Company Market Cap P/E Ratio Revenue YoY Growth Net Profit RSI
Sun Pharmaceutical 397,066 37.62 54,729 9.71% 10,980 34.03
Divis Laboratories 162,374 63.80 9,712 18.67% 2,191 53.67
Torrent Pharmaceuticals 140,631 60.97 11,539 6.99% 1,911 47.83
Lupin 106,665 22.48 22,910 13.74% 3,306 57.51
Dr Reddys Laboratories 102,845 18.32 33,741 16.73% 5,725 45.58
Cipla 99,317 21.81 28,410 7.12% 5,291 40.75
Zydus Life Science 92,111 18.06 23,511 18.55% 4,615 57.32
Mankind Pharma 85,822 47.03 12,744 20.90% 2,007 51.63
Aurobindo Pharma 78,373 22.33 32,346 9.43% 3,484 65.82
Alkem Laboratories 65,043 26.50 13,458 3.70% 2,216 53.68

Medicamen Biotech Company Announcements - News Screener

Screen MEDICAMEQ latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis.
Date Update Actions
2026-04-09 Announcement Under Regulation 30 (LODR) - Intimation Regarding Incorrect Event Disply On NSDL Portal -
2026-03-30 Closure of Trading Window -
2026-02-21 Disclosure Under Regulation 30 Of The SEBI (LODR) Regulations 2015 -
2026-02-18 Announcement under Regulation 30 (LODR)-Change in Management -
2026-02-16 Announcement under Regulation 30 (LODR)-Newspaper Publication -
2026-02-13 Announcement under Regulation 30 (LODR)-Change in Management -
2026-02-13 Unaudited Financial Results For The Quarter Ended On December 31 2025 -
2026-02-04 Board Meeting Intimation for Consideration Of Unaudited Consolidated And Standalone Financial Results Of The Company For The Quarter And Nine Months Ended December 31 2025. -
2026-01-16 Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 -
2026-01-07 Announcement Under Regulation 30 (LODR)- EU Approval For Product Registration Of Paracetamol -
2025-12-26 Closure of Trading Window -
2025-11-18 Announcement under Regulation 30 (LODR)-Newspaper Publication -
2025-11-14 Financial Results For The Quarter And Half Year Ended On September 30 2025 -
2025-11-05 Board Meeting Intimation for Consideration Of Unaudited Consolidated And Standalone Financial Results Of The Company For The Quarter And Half Year Ended On September 30 2025 -
2025-10-25 Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 -
2025-09-27 Closure of Trading Window -
2025-09-27 Shareholder Meeting / Postal Ballot-Scrutinizers Report -
2025-09-26 Shareholder Meeting / Postal Ballot-Outcome of AGM -
2025-09-04 Revised Intimation Of Book Closure In Accordance With Regulation 42 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 (Listing Regulations) -
2025-09-04 Intimation Of Book Closure In Accordance With Regulation 42 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 (Listing Regulations) -